On April 27, 2022, the Board of Directors of First Wave BioPharma, Inc. approved, effective immediately, an increase in the size of the Board from six directors to seven directors and appointed David Hoffman to serve as a member of the Board to fill the newly-created vacancy. Mr. Hoffman will hold this position until the next annual meeting of the Company's stockholders or until his successor is elected and qualified, subject to his earlier resignation or removal.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.7 USD | +2.66% | +5.06% | -35.71% |
20/05 | Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index | CI |
17/05 | First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.71% | 6.21M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- ENTO Stock
- News Entero Therapeutics, Inc.
- First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board